Overview

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this large comparative effectiveness study led by Richard J. Barohn, MD, of the University of Kansas Medical Center, is to learn about the safety and effectiveness of nortriptyline, duloxetine, pregabalin and mexiletine in treating cryptogenic sensory polyneuropathy (CSPN).
Phase:
Phase 4
Details
Lead Sponsor:
University of Kansas Medical Center
Collaborator:
Patient-Centered Outcomes Research Institute
Treatments:
Duloxetine Hydrochloride
Mexiletine
Nortriptyline
Pregabalin